Dr. Fyodor Urnov is the Co-Founder and Chair of the Scientific Advisory Board at Tune Therapeutics.
A pioneering presence in the field, Fyodor is Professor of Genetics, Genomics, and Development at UC Berkeley, and Scientific Director for Technology and Translation at the Innovative Genomics Institute. At the IGI, his focus is on establishing turnkey editability of the human genome and epigenome for clinical use, and on building the first in-human applications of CRISPR-based genome and epigenome editing therapeutics for sickle cell disease, immune system disorders, and neurodegeneration.
In his prior work at Sangamo BioSciences, he co-developed human genome editing with engineered nucleases, and co-led efforts to develop the functional toolbox of human epigenome editing as a disease therapeutic (2000-2003). He was also a key member of the team that developed the first in-human application of genome editing in 2009, and co-led teams developing the first in vivo epigenome editors for Huntington’s Disease and Tau dementia (2010-2016).
He received his Ph.D. in Biology from Brown University, and was a postdoctoral fellow at the National Institutes of Health in the laboratory of Dr. Alan P. Wolffe.